PortfoliosLab logo
PortfoliosLab logo
Tools
Performance Analysis
Portfolio Analysis
Factor Model
Portfolios
Lazy PortfoliosUser Portfolios
Discussions
ETFMG Treatments Testing and Advancements ETF (GER...
Performance
Risk-Adjusted Performance
Dividends
Drawdowns
Volatility

ETF Info

ISIN

US26924G7631

CUSIP

26924G763

Issuer

ETFMG

Inception Date

Jun 17, 2020

Region

North America (U.S.)

Leveraged

1x

Index Tracked

Prime Treatments, Testing and Advancements Index

Asset Class

Equity

Asset Class Size

Multi-Cap

Asset Class Style

Blend

Expense Ratio

GERM features an expense ratio of 0.68%, falling within the medium range.


Expense ratio chart for GERM: current value at 0.68% compared with the broader market ranging from 0.00% to 2.12%.0.50%1.00%1.50%2.00%0.68%

Share Price Chart


Loading data...

Compare to other instruments

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.


Popular comparisons:
GERM vs. SBIO
Popular comparisons:
GERM vs. SBIO

Performance

Performance Chart

The chart shows the growth of an initial investment of $10,000 in ETFMG Treatments Testing and Advancements ETF, comparing it to the performance of the S&P 500 index or another benchmark. All prices have been adjusted for splits and dividends.


0.00%500.00%1,000.00%1,500.00%2,000.00%2,500.00%Jun 02Jun 09Jun 16Jun 23Jun 30Jul 07Jul 14Jul 21Jul 28Aug 04Aug 11Aug 18Aug 25SeptemberSep 08
2,582.93%
151.47%
GERM (ETFMG Treatments Testing and Advancements ETF)
Benchmark (^GSPC)

Returns By Period


GERM

YTD

N/A

1M

N/A

6M

N/A

1Y

N/A

5Y*

N/A

10Y*

N/A

^GSPC (Benchmark)

YTD

23.11%

1M

-0.36%

6M

7.02%

1Y

23.15%

5Y*

12.80%

10Y*

11.01%

Monthly Returns

The table below presents the monthly returns of GERM, with color gradation from worst to best to easily spot seasonal factors. Returns are adjusted for dividends.


JanFebMarAprMayJunJulAugSepOctNovDecTotal
20240.00%0.00%0.00%
20230.00%0.00%0.00%0.00%0.00%
20220.00%0.00%0.00%0.00%
20210.00%0.00%0.00%0.00%
20200.00%0.00%
2017-7.06%-7.60%76.92%114.99%76.43%59.49%10.06%60.01%-25.95%5.95%58.44%12.08%2,155.13%
201618.97%18.97%

Risk-Adjusted Performance

Risk-Adjusted Performance Rank

The current rank of GERM is 7, meaning it’s performing worse than 93% of other ETFs on our website when it comes to balancing risk and reward. Below is a breakdown of how it compares using common performance measures.


The Risk-Adjusted Performance Rank of GERM is 77
Overall Rank
The Sharpe Ratio Rank of GERM is 44
Sharpe Ratio Rank
The Sortino Ratio Rank of GERM is 1212
Sortino Ratio Rank
The Omega Ratio Rank of GERM is 1515
Omega Ratio Rank
The Calmar Ratio Rank of GERM is 11
Calmar Ratio Rank
The Martin Ratio Rank of GERM is 55
Martin Ratio Rank
The risk-adjusted ranks indicate the investment's position relative to the market. A rank closer to 100 signifies top-performing investments, while a rank closer to 0 might suggest underperformance, based on the selected ratio. The values are calculated based on the past 12 months of returns.

Risk-Adjusted Performance Indicators

The charts below present risk-adjusted performance metrics for ETFMG Treatments Testing and Advancements ETF (GERM) and compare them to a chosen benchmark (^GSPC). These indicators evaluate an investment's returns against its associated risks.


Sharpe ratio
No data
GERM
^GSPC

There is not enough data available to calculate the Sharpe ratio for ETFMG Treatments Testing and Advancements ETF. We calculate this metric based on the past 12 months of trading data. Please check back later for updated information.


Rolling 12-month Sharpe Ratio
GERM (ETFMG Treatments Testing and Advancements ETF)
Benchmark (^GSPC)

Dividends

Dividend History

ETFMG Treatments Testing and Advancements ETF provided a 0.00% dividend yield over the last twelve months, with an annual payout of $19.50 per share.


0.00%$0.00$0.05$0.10$0.15$0.20$0.25$0.302020202120222023
Dividends
Dividend Yield
PeriodTTM2023202220212020
Dividend$19.50$0.24$0.14$0.10$0.29

Dividend yield

0.00%0.00%0.00%0.00%0.00%

Monthly Dividends

The table displays the monthly dividend distributions for ETFMG Treatments Testing and Advancements ETF. The dividends shown in the table have been adjusted to account for any splits that may have occurred.


JanFebMarAprMayJunJulAugSepOctNovDecTotal
2024$0.06$0.09$19.30$19.45
2023$0.09$0.06$0.04$0.05$0.24
2022$0.05$0.06$0.03$0.14
2021$0.06$0.04$0.00$0.10
2020$0.29$0.29

Drawdowns

Drawdowns Chart

The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.


0.00%Jun 02Jun 09Jun 16Jun 23Jun 30Jul 07Jul 14Jul 21Jul 28Aug 04Aug 11Aug 18Aug 25SeptemberSep 0800
GERM (ETFMG Treatments Testing and Advancements ETF)
Benchmark (^GSPC)

Worst Drawdowns

The table below displays the maximum drawdowns of the ETFMG Treatments Testing and Advancements ETF. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.

The maximum drawdown for the ETFMG Treatments Testing and Advancements ETF was 51.67%, occurring on Sep 14, 2017. Recovery took 52 trading sessions.


Depth

Start

To Bottom

Bottom

To Recover

End

Total

-51.67%Sep 4, 20178Sep 14, 201752Nov 27, 201760
-31.06%May 25, 20172May 26, 201715Jun 16, 201717
-30.52%May 10, 20175May 16, 20176May 24, 201711
-26.15%Jul 5, 201711Jul 19, 201713Aug 28, 201724
-23.35%Jan 5, 201715Jan 25, 201743Mar 30, 201758

Volatility

Volatility Chart

The chart below shows the rolling one-month volatility.


GERM (ETFMG Treatments Testing and Advancements ETF)
Benchmark (^GSPC)
PortfoliosLab logo
Performance Analysis
Portfolio AnalysisPortfolio PerformanceStock ComparisonSharpe RatioMartin RatioTreynor RatioSortino RatioOmega RatioCalmar RatioSummers Ratio
Community
Discussions


Disclaimer

The information contained herein does not constitute investment advice and made available for educational purposes only. Prices and returns on equities are listed without consideration of fees, commissions, taxes, penalties, or interest payable due to purchasing, holding, or selling.

Copyright © 2024 PortfoliosLab